topotecan has been researched along with aphidicolin in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (50.00) | 18.2507 |
2000's | 2 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kaufmann, SH | 1 |
Berger, NA; Chatterjee, S; Cheng, MF | 1 |
Albig, W; Doenecke, D; Kratzmeier, M; Meinl, A; Schliephacke, T | 1 |
Bhalla, K; Blaskovich, MA; Dunne, J; Gasparetto, M; Gentry, T; Haaland, P; Nimmanapalli, R; O'Bryan, E; Rizzieri, D; Sebti, S; Smith, C | 1 |
4 other study(ies) available for topotecan and aphidicolin
Article | Year |
---|---|
Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line.
Topics: Amsacrine; Aphidicolin; Blotting, Western; Camptothecin; Colony-Forming Units Assay; Cycloheximide; Daunorubicin; Deoxyadenosines; Dichlororibofuranosylbenzimidazole; Diterpenes; DNA Polymerase II; DNA Replication; Drug Synergism; Etoposide; Female; Humans; Leukemia, Promyelocytic, Acute; Mutagens; RNA; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured | 1991 |
Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens.
Topics: Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Aphidicolin; Camptothecin; Carmustine; Cell Cycle; Cell Death; Cell Line; Cisplatin; Cricetinae; Cricetulus; DNA Damage; DNA Repair; DNA, Neoplasm; Doxorubicin; Drug Synergism; Etoposide; Fibroblasts; Hydroxyurea; Lung; Melphalan; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 1994 |
The telomeric region is excluded from nucleosomal fragmentation during apoptosis, but the bulk nuclear chromatin is randomly degraded.
Topics: Aphidicolin; Apoptosis; Cell Line, Tumor; Cell Nucleus; Chromatin; Enzyme Inhibitors; HL-60 Cells; Humans; Kinetics; Micrococcal Nuclease; Nucleosomes; Recombinant Fusion Proteins; Saccharomyces cerevisiae; Telomere; Topotecan | 2004 |
Identification of compounds that enhance the anti-lymphoma activity of rituximab using flow cytometric high-content screening.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Aphidicolin; Apoptosis; Cell Cycle; Cell Line, Tumor; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; Lymphoma; Phenanthrolines; Rituximab; Topotecan | 2004 |